The global artificial intelligence (AI) in oncology market size accounted for USD 1.46 billion in 2024, grew to USD 1.87 billion in 2025, and is expected to be worth around USD 17.51 billion by 2034, poised to grow at a CAGR of 28.2% between 2024 and 2034. The Asia Pacific artificial intelligence (AI) in oncology market size is predicted to increase from USD 800 million in 2024 and is estimated to grow at the fastest CAGR of 28.32% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Artificial Intelligence (AI) in Oncology Market, by Component, 2024-2034
8.1.1. Software Solutions
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Hardware
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Artificial Intelligence (AI) in Oncology Market, by Cancer Type, 2024-2034
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Prostate Cancer
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Colorectal Cancer
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Brain Tumor
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Artificial Intelligence (AI) in Oncology Market, by Treatment Type, 2024-2034
10.1.1. Chemotherapy
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Radiotherapy
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Immunotherapy
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. Artificial Intelligence (AI) in Oncology Market, by End-Users, 2024-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Diagnostic Centers
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Pharmaceutical Companies
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Research Institutes
11.1.4.1. Market Revenue and Forecast (2021-2034)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Component (2021-2034)
12.1.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.1.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Component (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Component (2021-2034)
12.2.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.2.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Component (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Component (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Component (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Component (2021-2034)
12.3.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.3.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Component (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Component (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Component (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Component (2021-2034)
12.4.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.4.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Component (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Component (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Component (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Component (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-Users (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Component (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Cancer Type (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Treatment Type (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-Users (2021-2034)
13.1. IBM
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Azra AI
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Siemens Healthineers
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GE Healthcare
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Intel
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Path AI
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. NVIDIA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Concert.AI
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Digital Diagnostics Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Median Technologies
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample